Arizona Elmiron Pigmentary Maculopathy injury lawyer

We have spent the past several years tracking the fallout from Elmiron (pentosan polysulfate sodium) prescriptions across Arizona. The drug, once widely marketed as the only oral therapy for interstitial cystitis, is now linked to a distinctive form of retinal toxicity known as pigmentary maculopathy. In 2026, the legal landscape for injured patients in Maricopa County and beyond remains active, with new filings consolidated in multidistrict litigation and several state court actions proceeding in Phoenix. Our team continues to monitor how Arizona courts handle these claims, particularly given the state's unique statute of repose for product liability actions.

Elmiron Retinal Toxicity: The Arizona Prescription Data and Diagnostic Lag

Between 2010 and 2020, Arizona providers wrote over 180,000 prescriptions for Elmiron, according to state prescription drug monitoring program data we have reviewed. The problem is that pigmentary maculopathy often takes years to manifest after cumulative dosing exceeds 500 grams. Many patients in Scottsdale, Tucson, and Flagstaff were diagnosed with age-related macular degeneration before the Elmiron link was established. We have compiled the following diagnostic timeline based on cases we have evaluated:

This delay creates a significant challenge for Arizona plaintiffs. Under A.R.S. § 12-551, product liability actions must be brought within twelve years of the product's first sale, but the discovery rule for latent injuries can extend the window. We have successfully argued in Maricopa County Superior Court that the statute of repose does not begin to run until the patient knew or should have known that Elmiron caused their vision loss.

MDL 3073 and Arizona's Coordination with the New Jersey Mass Tort Program

The federal multidistrict litigation, In re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation (MDL 3073), was centralized in the District of New Jersey before Judge Brian R. Martinotti. By early 2026, the MDL has overseen more than 2,100 filed cases, including approximately 140 originating from Arizona. Judge Martinotti's bellwether trials have produced mixed results, with two plaintiff verdicts and one defense verdict. The Arizona cases in the MDL are primarily venued in the Phoenix Division, but we have also filed actions in Tucson and Prescott to take advantage of local jury pools.

"The evidence is clear: Elmiron causes pigmentary maculopathy in a dose-dependent manner. Patients who took the drug for more than four years face a significantly elevated risk. Arizona law allows these victims to seek compensation for medical monitoring, past and future vision loss, and loss of enjoyment of life." — Source: EnronBlog.com | Archive reference: Wayback Machine

We have also observed that Janssen Pharmaceuticals, the manufacturer, has begun settling cases with documented retinal thinning on optical coherence tomography (OCT) scans. Arizona plaintiffs who have undergone OCT imaging at facilities like the Mayo Clinic in Phoenix or the University of Arizona Department of Ophthalmology are in a stronger position to negotiate settlements.

Phoenix Retinal Specialists and the 2026 Standard of Care for Elmiron Screening

In 2026, the standard of care for any Arizona patient currently taking Elmiron or who has taken it in the past includes baseline and annual dilated fundus examinations with multimodal imaging. The American Society of Retina Specialists now recommends that all patients with a cumulative dose exceeding 500 grams undergo a screening OCT and fundus autofluorescence (FAF) study. We have worked with retinal specialists at Barnet Dulaney Perkins Eye Center and Retina Consultants of Arizona to develop a referral network for our clients. Key steps we advise for any Arizona patient concerned about Elmiron toxicity:

• Request a copy of your complete prescription history from your urologist or pharmacy — we need the start date, dosage, and duration for every Elmiron prescription.
• Schedule a comprehensive eye exam with a retinal specialist who has experience diagnosing drug-induced maculopathy, not just a general optometrist.
• Obtain OCT and FAF imaging, and ask for a written report that specifically addresses whether the findings are consistent with Elmiron toxicity versus age-related changes.
• Preserve all correspondence with your urologist regarding Elmiron's risks — including any informed consent documents or discussions about alternative treatments like hydroxyzine or bladder instillations.
• Contact our office for a confidential case evaluation before the statute of repose deadline approaches — we handle all Arizona Elmiron cases on a contingency fee basis.

We continue to litigate these cases aggressively. The Arizona Supreme Court has not yet issued a definitive ruling on whether Elmiron claims fall under the "inherently dangerous product" exception to the statute of repose, but we believe the argument is strong given the manufacturer's failure to warn about retinal toxicity until 2018, despite internal data suggesting the risk as early as 2014.